DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chronic Urticaria or Hives - Pipeline Review, H1 2017" report to their offering.
Chronic Urticaria Or Hives - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 3, 3, 1 and 3 respectively.
Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Chronic Urticaria Or Hives - Overview
- Chronic Urticaria Or Hives - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Chronic Urticaria Or Hives - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
- Biofrontera AG
- ELORAC Inc
- Faes Farma SA
- Genentech Inc
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd
- J Uriach Y Compania SA
- Mycenax Biotech Inc
- Novartis AG
- Panacea Biotec Ltd
Synermore Biologics Co Ltd
For more information about this report visit http://www.researchandmarkets.com/research/h5lm6r/chronic_urticaria